First in human intraarterial delivery of tislelizumab for the treatment of pMMR locally advanced rectal cancer: A single-arm, open label, phase II clinical trial.

Transl Oncol · 2024 · PMC11736401 · PMID 39405605

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A 3-year follow up of the NRG-GI002 trial showed a trend toward better OS after the addition of pembrolizumab to TNT despite lack of difference in NAR score, pCR rate or DFS [ 35 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.